The DOI matches its Crossref record; 114 of the 117 references it cites were found in a registry or an index; 25 of the 152 sources its claims cite were checked for support.
The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities
Open accessAbstract
Purpose of Review: This review examines lifestyle modification for obesity management with the goal of identifying treatment components that could support the use of a new generation of anti-obesity medications (AOMs). Recent Findings: Semaglutide reliably reduces baseline body weight by approximately 15% at 68 weeks, in contrast to 5–10% for lifestyle modification. Tirzepatide induces mean losses as great as 20.9%. Both medications reduce energy intake by markedly enhancing satiation and decreasing hunger, and they appear to lessen the need for traditional cognitive and behavioral strategies (e.g., monitoring food intake) to achieve calorie restriction. Little, however, is known about whether patients who lose weight with these AOMs adopt healthy diet and activity patterns needed to optimize body composition, cardiometabolic health, and quality of life. Summary: When used with the new AOMs, the focus of lifestyle modification is likely to change from inducing weight loss (through calorie restriction) to facilitating patients’ adoption of dietary and activity patterns that will promote optimal changes in body composition and overall health.
Overview
CoChat Summary
TL;DR
This review argues that with second-generation anti-obesity medications (AOMs), lifestyle modification’s focus shifts from inducing weight loss through calorie restriction to helping patients adopt healthy diet and activity patterns for optimal body composition and overall health. It summarizes semaglutide and tirzepatide efficacy and identifies major knowledge gaps in diet quality, physical activity, body composition, and psychosocial outcomes.
Key findings
- Semaglutide 2.4 mg reduces baseline body weight by approximately 15% at 68 weeks, and tirzepatide induces mean losses as great as 20.9%, compared with 5–10% for lifestyle modification alone. In STEP 1, semaglutide produced a mean 14.9% loss versus 2.4% for placebo; in SURMOUNT-1, tirzepatide 15 mg produced 20.9% versus 3.1% for placebo.
- Adding intensive lifestyle modification to semaglutide did not clearly increase long-term weight loss: STEP 3 found 16.0% loss with semaglutide plus intensive behavioral therapy and meal replacements versus 5.7% with placebo, only about 1.1 percentage points more than STEP 1’s less intensive counseling. In SURMOUNT-3, after a 12-week intensive lifestyle lead-in (6.9% loss), tirzepatide added 18.4% from randomization, for a cumulative 24.3% reduction versus 4.5% for placebo.
- Weight regain after discontinuation is substantial: in a STEP 1 extension subset, participants who lost a mean 17.3% at 68 weeks regained an average 11.6 percentage points (about two-thirds) one year after stopping medication; in STEP 4, participants switched to placebo regained 4.9 percentage points, while those continuing semaglutide lost an additional 6.8%.
- Safety findings include gastrointestinal adverse events that were typically mild to moderate; discontinuation due to adverse events was approximately 6–7% with semaglutide 2.4 mg or tirzepatide 10–15 mg versus 2.5–3% for placebo. Semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in persons with overweight/obesity and a history of cardiovascular disease but not type 2 diabetes.
Methods
- Narrative review examining lifestyle modification for obesity management alongside second-generation AOMs, principally semaglutide 2.4 mg and tirzepatide, including mechanisms, efficacy, safety, and clinical considerations.
- Evidence base includes published phase 3 STEP and SURMOUNT trials, other randomized trials and guidelines, and the authors’ clinical observations; a summary table reports end-of-treatment changes in seven STEP trials and three SURMOUNT trials.
- Main analysis is a qualitative synthesis and interpretation; no systematic search, meta-analysis, or primary data collection is reported.
Limitations
- Stated: little is known about whether patients who lose weight with these AOMs adopt healthy diet and activity patterns; no results have been published on baseline dietary intake, macronutrient changes, meal/snack timing, or problem eating, and few data exist on physical activity or cardiorespiratory fitness.
- Stated: body composition findings require verification—STEP 1 supplementary data suggested roughly 40% of weight loss came from lean mass, while SURMOUNT-1 suggested approximately 25%, and older-participant estimates are limited by small numbers; psychosocial outcomes including mood and suicidal ideation have not been fully reported.
- Evident: as a narrative review, it does not systematically appraise or quantitatively pool evidence, and many recommendations are based on existing guidelines and clinical observations rather than randomized trials, as the authors acknowledge.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
12 Valid · 3 Not valid · 103 Not checked · 29 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Regular self-monitoring also facilitates increased physical activity [8–12].”
§ The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities > Behavioral and Psychosocial Issues, Including Terminating AOMs > Self-Monitoring of Diet and Physical Activity
What the sources say
- Supportedcites [8] Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020;75(2):235–51. source
The Behavior Therapy section (page not provided) describes self-monitoring of physical activity as a cornerstone of treatment and says record keeping helps people identify patterns and target changes. This supports the claim that regular self-monitoring facilitates increased physical activity. (LLM, conf=0.86)
- Not checked yetcites [9] The Diabetes Prevention Program Research Group. The Diabetes Prevention Program (DPP). Description of lifestyle intervention Diabetes Care. 2002;25(12):2165–71.
- Disputedcites [10] Wing RR, Tate DF, Gorin AA, Raynor HA, Fava JL. A self-regulation program for maintenance of weight loss. N Engl J Med. 2006;355(15):1563–71. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) explicitly identifies a failure to find differences in activity as a limitation of the trial. Although participants were taught to use self-weighing data to regulate exercise, the paper does not report the claimed increase in physical activity. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
- Supportedcites [11] Look AHEAD Research Group, Wadden TA, West DS, Delahanty L, Jakicic J, Rejeski J, et al. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring). 2006;14(5):737–52. source
The Lifestyle Activity section says Look AHEAD participants increase their activity in part by using a pedometer and are instructed to raise their daily step count each week. This supports the claim that regular activity monitoring can facilitate increased physical activity, though the example is specifically pedometer use in this intervention. (LLM, conf=0.85)
- Partly supportedcites [12] Wadden TA, Tsai AG, Tronieri JS. A protocol to deliver intensive behavioral therapy (IBT) for obesity in primary care settings: the MODEL-IBT program. Obesity (Silver Spring). 2019;27(10):1562–6. sourceExperimental — accuracy not yet measured
In “Dissemination of the MODEL-IBT Protocol” (page unavailable), the paper recommends regularly monitoring physical activity. It does not state that self-monitoring facilitates an increase in physical activity; that effect is the unsupported part of the claim. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These reductions are associated in a generally linear manner with improvements in cardiovascular disease (CVD) risk factors, quality of life, and prevention of type 2 diabetes [24–26].”
§ The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities > Lifestyle Modification for Overweight and Obesity > End-of-Treatment Outcomes
What the sources say
- Partly supportedcites [24] Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481–6. sourceExperimental — accuracy not yet measured
The Results (Categorical changes in weight; page not provided) report a strong graded association between greater weight loss and improvements in several CVD risk factors, though not LDL cholesterol. The Methods (Assessments; page not provided) measure risk factors, not quality of life or diabetes prevention; all participants already had type 2 diabetes. Those two outcomes are not supported by this paper. (LLM, conf=0.88)
- Partly supportedcites [25] Kolotkin RL, Fujioka K, Wolden ML, Brett JH, Bjorner JB. Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clin Obes. 2016;6(4):233–42. sourceExperimental — accuracy not yet measured
The 'Categorical weight loss and health-related quality of life' section reports greater improvement in some quality-of-life scores at higher weight-loss levels, including in the placebo arm. It does not establish a generally linear relationship, and the paper does not report that these weight reductions improved CVD risk factors or prevented type 2 diabetes. Page numbers are unavailable in our copy. (LLM, conf=0.88)
- Not checked yetcites [26] Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29(9):2102–7. source
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Both medications reduce energy intake by markedly enhancing satiation and decreasing hunger, and they appear to lessen the need for traditional cognitive and behavioral strategies (e.g., monitoring food intake) to achieve calorie restriction.”
- Also stated in: § Second-Generation AOMs: Mechanisms of Action and Safety Findings · hedged
“By consistently reducing hunger (which initiates eating), increasing satiation and satiety (which terminate meal intake and extend the inter-meal interval, respectively), and potentially decreasing hedonic eating [45–47], the authors view the new-generation AOMs as reducing patients’ responsiveness—or vulnerability—to the toxic food environment.”
§ The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities > Abstract > Recent Findings
What the sources say
- Partly supportedcites [45] Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care. 2023;46(5):998–1004. sourceExperimental — accuracy not yet measured
The Results sections on Fasting Appetite and Energy Intake During Ad Libitum Buffet-Style Lunch report decreased hunger and lower lunch energy intake with both drugs. They measured fasting satiety and fullness, not meal-related satiation, and did not establish that enhanced satiation caused the reduction in intake. The Conclusions also caution that measuring one meal may not reflect total energy intake. (LLM, conf=0.86)
- Partly supportedcites [46] Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Rønne J, Alanentalo T, Baquero AF, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6): e133429. sourceExperimental — accuracy not yet measured
The Results report that semaglutide suppressed food intake in diet-induced obese rodents, and the Introduction reports reduced energy intake in small human trials. The paper discusses a possible meal-termination pathway, but does not establish that semaglutide markedly enhances satiation and decreases hunger. It does not address tirzepatide or a reduced need for cognitive and behavioral strategies; page numbers are unavailable in our copy. (LLM, conf=0.87)
- Partly supportedcites [47] Wharton S, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring). 2023;31(3):703–15. sourceExperimental — accuracy not yet measured
The Introduction reports that semaglutide reduced energy intake in shorter clinical studies, and the Conclusion reports reduced hunger and increased fullness. The paper does not address tirzepatide, so it cannot support the claim about both medications. The Discussion also notes that differences in hunger and fullness between semaglutide and placebo were not statistically significant at weeks 52 and 104. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Second-Generation AOMs: Mechanisms of Action and Safety Findings · hedged
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Limitations of lifestyle modification include the plateauing of weight loss at 6–9 months [30], even when participants still have obesity and may receive continued counseling [6, 31].”
§ The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities > Lifestyle Modification for Overweight and Obesity > Post-Treatment Outcomes and Challenges
What the sources say
- Partly supportedcites [30] Butryn ML, Webb V, Wadden TA. Behavioral treatment of obesity. Psychiatr Clin North Am. 2011;34(4):841–59. sourceExperimental — accuracy not yet measured
The Effectiveness of behavioral treatment section states that 'Weight loss often reaches its peak at approximately 6 months, and then weight regain often begins in the absence of weight maintenance therapy,' which supports the substance of the claim — that plateauing/regain after roughly half a year is a limitation of lifestyle modification. However, our copy gives the timing as approximately 6 months (and elsewhere describes regain beginning after 6 months of loss, e.g. the Wadden et al. trial in Long-term patient-provider contact, and the primary-care counseling trial where participants 'regained their weight between month 6 and month 12'), not a 6–9 month window; the upper bound of the cited range is not stated in the source. The source also hedges the point ('often reaches its peak… often begins') and explicitly conditions the regain on the absence of weight maintenance therapy, whereas the citing sentence presents the plateau as an unqualified fact of lifestyle modification. (LLM, conf=0.70)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“in contrast to 5–10% for lifestyle modification”
- Also stated in: § End-of-Treatment Outcomes · plain
“Such regimens typically induce a mean 5–10% reduction in baseline weight at 1 year (compared with 1–2% for controls), as in the Diabetes Prevention Program and Look AHEAD trials [6, 8, 20–22].”
§ The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities > Abstract > Recent Findings
What the sources say
- Not checked yetcites [6] Jensen MD, Ryan DH, Donato KA, Apovian CM, Ard JD, Comuzzie AG, et al. Guidelines (2013) for managing overweight and obesity in adults. Obesity. 2014;22(S2):S1–410.
- Supportedcites [8] Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020;75(2):235–51. source
The Conclusion states that high-intensity lifestyle modification programs can help adults with overweight or obesity lose 5–10% of initial weight. The short-term efficacy section also reports mean losses of about 8% at one year, supporting the 5–10% contrast in the citing sentence. (LLM, conf=0.93)
- Not checked yetcites [20] Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. source
- Partly supportedcites [21] Wadden TA, West DS, Neiberg RH, Wing RR, Ryan DH, Johnson KC, et al. One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring). 2009;17(4):713–22. sourceExperimental — accuracy not yet measured
The Discussion reports a mean one-year loss of 8.6% with the intensive lifestyle intervention, supporting the cited 5–10% figure for this trial. It does not establish that this range is typical of lifestyle modification generally; the Discussion says generalizability to primary care is unknown. The reported control-group loss was 0.7%, not 1–2%. (LLM, conf=0.88)
- Not checked yetcites [22] Haywood C, Sumithran P. Treatment of obesity in older persons—a systematic review. Obes Rev. 2019;20(4):588–98. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § End-of-Treatment Outcomes · plain
84 more claims · 7 with their cited sources checked
Create a free account to see all 147 claims and to verify the 127 references still open.
- It may state two separate claims as one. 46
- Probably not a substantial claim. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tailored nutritional strategies—including hypocaloric diets enriched in protein and fiber, as well as amino acid, vitamin, and mineral supplementation—are critical to preserve lean mass and support sustained weight maintenance.”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Behavioural strategies may improve eating behaviours, dietary quality and adherence during GLP-1 RA use, although the longer-term psychological and behavioural impacts following medication cessation remain poorly understood and warrant further investigation [11].”
From Bridging the nutrition guidance gap for GLP-1 receptor agonist therapy assisted weight loss: Lessons from bariatric surgery (2026) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Some authors have shown that AOMs are more effective in WL than the lifestyle approach alone [62,125]”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [62]
In the citing paper
“Diet quality enables greater and sustained WL in the long term, whereas side effects can affect metabolic health [62].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [62]
In the citing paper
“for example, Wadden et al. reported that WL induced by lifestyle modification is approximately 5–10% [62].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [62]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities > Efficacy of Semaglutide 2.4 mg for Overweight/Obesity > Post-treatment Outcomes and Challenges
“when randomly switched to placebo, regained 4.9% percentage points (about half) in the ensuing 48 weeks”
§ The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities > Efficacy of Semaglutide 2.4 mg for Overweight/Obesity > End-of-Treatment Outcomes in Selected Trials
“Switched to placebo + lifestyle intervention (268) | 6.9”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities > Efficacy of Tirzepatide for Overweight and Obesity > End-of-Treatment Outcomes in Selected Trials
“SURMOUNT-3 examined the effects of administering tirzepatide 10–15 mg/day”
§ The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities > Efficacy of Tirzepatide for Overweight and Obesity
“The safety and efficacy of once-weekly tirzepatide for overweight and obesity are being evaluated in the SURMOUNT trials”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“These participants lost approximately five percentage points less body weight than those in SURMOUNT-1”
§ The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities > Efficacy of Tirzepatide for Overweight and Obesity > End-of-Treatment Outcomes in Selected Trials
Reported 5 · recomputed 6.7
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 2×
“Similarly, the benefits of more moderate weight loss, achieved at a low cost with traditional lifestyle modification, should not be overlooked in preventing type 2 diabetes [20] or in reducing mild elevations in blood pressure and other cardiometabolic risk factors [24].”
Background(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Child abuse: Adolescent records vs. adult recall
Femina, D. D., Yeager, C. A., & Lewis, D. O. (1990) · Child Abuse & Neglect · doi:10.1016/0145-2134(90)90033-p · Cited by 8,820
A Clinical Trial of the Effects of Dietary Patterns on Blood Pressure
Appel, L. J., Moore, T. J., Obarzanek, E., Vollmer, W. M., Svetkey, L. P., Sacks, F. M., Bray, G. A., Vogt, T. M., Cutler, J. A., Windhauser, M. M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704173361601 · Cited by 5,981
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationPosner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
Overweight, Obesity, and Depression: A Systematic Review and Meta-analysis of Longitudinal Studies
Luppino, F. S., de Wit, L. M., Bouvy, P. F., Stijnen, T., Cuijpers, P., Penninx, B. W. J. H., & Zitman, F. G. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.2 · Cited by 4,322
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800389 · Cited by 3,616 · cited 1×
“Dietary strategies can be based on the patient’s comorbidities, as well as sociocultural preferences [88], and incorporate reduced-calorie versions of the US Dietary Guidelines [87], a Mediterranean-style diet [89], the DASH diet [90], or a variety of other approaches [6, 88].”
Background
Research works printed but not linked: 5
- Jensen MD, Ryan DH, Donato KA, Apovian CM, Ard JD, Comuzzie AG, et al. Guidelines (2013) for managing overweight and obesity in adults. Obesity. 2014;22(S2):S1–410.
- Guyenet SJ. The hungry brain: outsmarting the instincts that make us overeat. New York: Flatiron Books; 2017.
- U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary guidelines for Americans, 2020–2025. 9th Edition. December 2020. Available at: DietaryGuidelines.gov.
- Patel JJ, Mundi MS, Martindale RG, Hurt RT. Obesity. In: Mueller CM, editor. The ASPEN adult nutrition core curriculum. 3rd ed. Silver Spring, MD: American Society for Parenteral and Enteral Nutrition; 2017. p. 1028–58.
- Sogg S, Gorman MJ. Interpersonal changes and challenges after weight-loss surgery. Prim Psychiatry. 2008;15(8):61–6.
Cited by
Medications for Obesity: A Review
Gudzune, K. A., & Kushner, R. F. (2024) · JAMA · doi:10.1001/jama.2024.10816 · Cited by 263
Nutritional considerations with antiobesity medications
Almandoz, J. P., Wadden, T. A., Tewksbury, C., Apovian, C. M., Fitch, A., Ard, J. D., Li, Z., Richards, J., Butsch, W. S., Jouravskaya, I., et al. (2024) · Obesity · doi:10.1002/oby.24067 · Cited by 134
“Therefore, consideration should be given to recommending supplementation with a complete multivita-min, calcium, and vitamin D as appropriate for patients receiving AOMs [71].”
BackgroundInfluentialSelf-citationChristensen, S., Robinson, K., Thomas, S., & Williams, D. R. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100121 · Cited by 108
“Although multiple nutritional concerns exist for individuals with overweight/obesity, little guidance is available for those pursuing treatment with GLP-1 or GIP/GLP-1 RAs [50].”
BackgroundApproach to Obesity Treatment in Primary Care: A Review
Yanovski, S. Z., & Yanovski, J. A. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.8526 · Cited by 103
Wadden, T. A., Brown, G. K., Egebjerg, C., Frenkel, O., Goldman, B., Kushner, R. F., McGowan, B., Overvad, M., & Fink-Jensen, A. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.4346 · Cited by 96
Self-citation
Metadata
- Authors
- Wadden, T. A., Chao, A. M., Moore, M., Tronieri, J. S., Gilden, A., Amaro, A., Leonard, S., & Jakicic, J. M.
- Affiliations
- University of Pennsylvania (US)
- Johns Hopkins University (US)
- University of Colorado Anschutz (US)
- University of Kansas Medical Center (US)
- Corresponding author
- Wadden, Thomas A.
- ORCID
- Venue
- Current Obesity Reports
- Published
- 2023-12-02
- Volume
- 12
- Issue
- 4
- Pages
- 453-473
- ISSN
- 2162-4968 (ISSN-L)
- PMC
- PMC10748770
- OpenAlex
- W4389267144
- Cited by
- 129
- References
- 117
- Citations by year
- 2026: 30 · 2025: 52 · 2024: 47
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Current Obesity Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- lifestyle modification, anti-obesity drugs, obesity treatment, semaglutide, tirzepatide, weight loss, satiety, hunger, caloric restriction, dietary habits, physical activity, body composition, cardiometabolic health, quality of life
- MeSH terms
- Body Weight, Humans, Life Style, Obesity, Quality of Life, Exercise, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities. https://app.cochat.ai/papers/10.1007/s13679-023-00534-z
- The paper
- Wadden, T. A., Chao, A. M., Moore, M., Tronieri, J. S., Gilden, A., Amaro, A., Leonard, S., & Jakicic, J. M. (2023). The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities. Current Obesity Reports. https://doi.org/10.1007/s13679-023-00534-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.